Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
New Strategies for Individualizing Treatment in DME
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Vera Bril, MD
Nicholas J. Silvestri, MD
Diagnostic Advances in gMG: Effective Tools and Techniques
Hans Katzberg, MD
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Neelam Goyal, MD
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Ocular to Generalized MG: How and Why the Disease Evolves
Acromegaly Care: Individualized Diagnosis and Management Strategies
July 13, 2025
San Francisco, California
Trial in Progress: Phase 3 MoonRISe-3 Study
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Evolving Strategies for Sustained-Release Glaucoma Treatments
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
New Solutions for Optimizing IOP Control: A Case-Based Approach
What’s New in Schlemm’s Canal MIGS?
Effective MIGS for Optimal IOP Control: A Case-Based Approach
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.